Defective fas ligand expression and activation-induced cell death in the absence of IL-2-Inducible T cell kinase

被引:68
作者
Miller, AT
Berg, LJ
机构
[1] Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA 01655 USA
[2] Univ Massachusetts, Med Ctr, Program Immunol & Virol, Worcester, MA 01655 USA
关键词
D O I
10.4049/jimmunol.168.5.2163
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The Tec family tyrosine kinase, IL-2-inducible T cell kinase (Itk), plays an important role in TCR signaling. Studies of T cells from Itk-deficient mice have demonstrated that Itk is critical for the activation of phospholipase-Cgamma1, leading to calcium mobilization in response to TCR stimulation. This biochemical defect results in reduced IL-2 production by Itk-deficient T cells. To further characterize the downstream effects of the Itk deficiency, we crossed Itk(-/-) mice to a TCR-transgenic line and examined T cell responses to stimulation by peptide plus APC. These studies show that Itk is required for maximal activation of early growth responses 2 and 3 and Fas ligand transcription after TCR stimulation. These transcriptional defects lead to reduced activation-induced cell death of stimulated Itk(-/-) T cells, both in vitro and in vivo. Together these studies define an important role for Itk in TCR signaling, leading to cytokine gene expression and activation-induced cell death.
引用
收藏
页码:2163 / 2172
页数:10
相关论文
共 76 条
[71]  
Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.3.CO
[72]  
2-2
[73]   Alterations in CD4 dependence accompany T cell development and differentiation [J].
Yelon, D ;
Spain, LM ;
Lim, K ;
Berg, LJ .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (07) :1077-1090
[74]   Regulation of Fas ligand expression during activation-induced cell death in T cells by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase [J].
Zhang, J ;
Gao, JX ;
Salojin, K ;
Shao, Q ;
Grattan, M ;
Meagher, C ;
Laird, DW ;
Delovitch, TL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (06) :1017-1029
[75]  
Zheng LX, 1998, J IMMUNOL, V160, P763
[76]  
Zhu L, 1999, IMMUNOLOGY, V97, P26